price month
 close
price
underwhelm rova-t data limit opportun much-hyp
pipelin asset announc result triniti trial rova-t
third-lin treatment patient small cell lung cancer
sclc drug show overal respons rate patient
high express although high clearli defin orr
assess independ review committe
level efficaci close seen regimen across
entir sclc set safeti profil also concern lead
us wonder drug would actual fit clinic practic
decreas target price rova-t could end show
benefit sclc tumor type monotherapi combin
immunotherapi bristol-my squibb opdivo and/or yervoy
remov sale product model along
chang explain lower target price base
split dcf valuat rel valuat price-to-earnings
ep estim
main upsid risk call stronger
expect humira growth unexpect pipelin success
main downsid risk humira erod faster expect addit
question pipelin re-emerg pursu acceler
approv rova-t believ rais question around strength
pipelin may still opportun rova-t market
would like much smaller compani guidanc peak
sale concern saw elev expect
pipelin follow recent run stock today news
result stock reaction highlight fear expect take
time stock begin recov
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
competit landscap sclc rapidli chang studi opdivo
monotherapi opdivo yervoy combin
sclc expect read base previous
releas data believ opdivo yervoy combo better overal profil
rova-t sclc look see full data rova-t studi gain
better understand clinic profil asset particular eye data
entir studi dll high subset patient present today
risk acquir rova-t buy-out stemcentrx
surpris mani investor pressur compani show
deal worth cost data instil confid futur
product platform rova-t one mani asset provid
mid-to-long term sale guidanc earn call guid
toward nomin sale exclud humira includ sale
pipelin drug elagolix upadacitinib risankizumab compani
anticip sale upadacitinib risankizumab alon given
crowd immunolog market believ number may
aggress especi given safeti concern upadactinib
product file regul year set stage potenti approv
launch also suggest next sever month rel
quiet period catalyst perspect await meaning
figur comparison object respons rate orr current sclc treatment regimen
price rate neutral target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
research-bas pharmaceut compani broad
sustain portfolio market-lead proprietari
pharmaceut biolog sold world-wide
blue sky valuat base greater sale
humira imbruvica market product compar
current base case assumpt blue sky valuat base
dcf driven wacc termin valu
grey sky valuat base lower sale humira
imbruvica market product compar current base
case assumpt grey sky valuat base dcf driven
wacc termin valu
 close
compani mention price
vamil divan md certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
